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Abstract
Background: Methylation-mediated silencing of genes is one epigenetic mechanism implicated in
cancer. Studies regarding the role of modulation of gene expression utilizing inhibitors of DNA
methylation, such as decitabine, in osteosarcoma (OS) have been limited. A biological
understanding of the overall effects of decitabine in OS is important because this particular agent
is currently undergoing clinical trials. The objective of this study was to measure the response of
the OS cell line, U2OS, to decitabine treatment both in vitro and in vivo.
Results: Microarray expression profiling was used to distinguish decitabine-dependent changes in
gene expression in U2OS cells, and to identify responsive loci with demethylated CpG promoter
regions. U2OS xenografts were established under the sub-renal capsule of immune-deficient mice
to study the effect of decitabine in vivo on tumor growth and differentiation. Reduced nuclear
methylation levels could be detected in xenografts derived from treated mice by
immunohistochemistry utilizing a 5-methylcytidine antibody. Decitabine treatment reduced tumor
xenograft size significantly (p < 0.05). Histological analysis of treated U2OS xenograft sections
revealed a lower mitotic activity (p < 0.0001), increased bone matrix production (p < 0.0001), and
a higher number of apoptotic cells (p = 0.0329). Microarray expression profiling of U2OS cultured
cells showed that decitabine treatment caused a significant induction (p < 0.0025) in the expression
of 88 genes. Thirteen had a ≥2-fold change, 11 of which had CpG-island-associated promoters.
Interestingly, 6 of these 11 were pro-apoptotic genes and decitabine resulted in a significant
induction of cell death in U2OS cells in vitro (p < 0.05). The 6 pro-apoptotic genes (GADD45A,
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HSPA9B, PAWR, PDCD5, NFKBIA, and TNFAIP3) were also induced to ≥2-fold in vivo. Quantitative
methylation pyrosequencing confirmed that the tested pro-apoptotic genes had CpG-island DNA
demethylationas a result of U2OS decitabine treatment both in vitro and in xenografts
Conclusion: These data provide new insights regarding the use of epigenetic modifiers in OS, and
have important implications for therapeutic trials involving demethylation drugs. Collectively, these
data have provided biological evidence that one mode of action of decitabine may be the induction
of apoptosis utilizing promoter-CpG demethylation of specific effectors in cell death pathways in
OS.
Background
Epigenetic modifications involve genomic methylation
changes and the alteration of chromatin-associated pro-
teins such as linker histones, polycomb groups, nuclear
scaffold proteins and transcription factors, (reviewed in
[1]). Epigenetic abnormalities contribute in several ways
to oncogenesis and may activate oncogenes or silence
tumor suppressor genes. In addition, epigenetic processes
can enhance chromosomal instability [2], (reviewed in
[3]), and have recently been shown to be involved in the
regulation of the DNA double-strand break and repair
process [4], (reviewed in [5]). Typically, a general pattern
of demethylation of the genome is observed in tumor
DNA, while increased methylation of a subset of pro-
moter-associated CpG islands associated with the tran-
scriptional start sites (TSS) of genes may also be observed.
Abnormal methylation of genes is far more frequent than
classical genetic mutation.
There is increasing interest in the therapeutic modulation
of such processes, since epigenetic alterations are amena-
ble to physiological alteration by drugs that change pat-
terns of DNA methylation or histone acetylation,
(reviewed in [6]). The most powerful DNA methyltrans-
ferase inhibitor in clinical use is 5-aza-2'-deoxycytidine
(decitabine). Decitabine is a cytosine analog that inhibits
DNA methylation and reactivates silenced genes. Decitab-
ine has shown promising clinical efficacy in the treatment
of myelodysplastic syndromes, with evidence of gene tar-
get expression modulation by demethylation with less
toxicity than conventional cancer chemotherapies [7,8].
Studies regarding the implications of epigenetic modifica-
tion in osteosarcoma (OS) have been limited, but have
suggested a role in bone differentiation [9-11], transcrip-
tion factor expression, and histone modifications [12,13].
No study to date has utilized decitabine to modify gene
expression in an OS-derived cell to identify gene-specific
targets for demethylation that may have therapeutic
importance.
A full assessment of tumor cell response to treatment
requires integrating experimental data from both in vitro
and in vivo observations. One major advantage of preclin-
ical animal models of xenografts of human tumor cell
lines is that they provide both tissue vascularization and a
tumor microenvironment that is closer to human tumors
so that an evaluation of the therapeutic impact on tissue
differentiation, cell growth and proliferation levels is pos-
sible [14], (reviewed in [15]). Such analyses are providing
opportunities for a detailed assessment of new classes of
anti-neoplastic drugs that target the epigenome, such as
decitabine.
Results
Effects of decitabine on U2OS cells in vitro
Decitabine is a cytotoxic agent in addition to being a
demethylation agent. U2OS growth rate was measured in
the absence, or presence of 1 µM decitabine. This rela-
tively low-dose was chosen to minimize cytotoxicity. The
doubling time for U2OS in the absence of 1 µM decitab-
ine was close to 2.75 days (66 hours) while the decitabine
treated U2OS cells doubled at 3.5 days (84 hours). This
was accompanied by a minor reduction in viable cell
numbers as a result of decitabine treatment (Figure 1A).
To confirm that decitabine was also causing DNA demeth-
ylation of specific loci we examined the extent of loss of
the methylation known to characterize the small nuclear
ribonucleoprotein polypeptide N (SNRPN) gene. This
heavily methylated gene has previously been shown to
undergo reduction in methylation following treatment
with decitabine [16]. After 72 hours treatment of U2OS
with 1 µM decitabine, ~60 % more DNA could be digested
with a methylation-sensitive restriction endonuclease [see
Additional file 1]. To determine whether a slower growth
rate was accompanied by higher level of cell death follow-
ing decitabine treatment, death assessment was studied by
flow cytometry after PI staining. The control (no-treat-
ment) cells showed a 5% death rate whereas the decitab-
ine treatment significantly increased the death rate of 10%
more than the control at day 3 (p < 0.05) (Figure 1B).
Effects of decitabine on U2OS in vivo
U2OS has been shown to be generally non-tumorigenic
using heterotopic grafts under the mouse skin [17]. In
contrast the sub-renal capsule site has proved to be an
excellent grafting site for xenografts in general [18-20].
Therefore U2OS xenografts were obtained from mice and
cut into pieces of ~4 mm3 and 24 tumor tissue pieces wereCancer Cell International 2007, 7:14 http://www.cancerci.com/content/7/1/14
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regrafted under the renal capsules of 6 SCID mice (4 grafts
per mouse). Four weeks after grafting the host mice were
divided into two groups. One group of three mice was
treated with Decitabine (2.5 mg/kg) intraperitoneally on
Days 29, 31 and 33. The other group of three mice was
given saline as control at the same schedule. On Day 37,
all 6 mice were sacrificed and xenografts were dissected
from the mice, and the tumor volumes were measured
and compared in both treatment arms. The effectiveness
of demethylation in vivo was determined by analyzing the
relative cellular distribution of 5-methylcytidine levels
using a specific 5-methylcytidine antibody and 6 tissue
sections from 6 xenografts (3 control and 3 decitabine
treated). In these analyses, nuclei in host kidney stromal
cells were used as internal positive controls (see dark
staining nuclei Figure 2). Negative controls obtained by
omitting the primary antibody were also performed.
Nuclear xenograft tumor staining was recorded by a sem-
iquantitative and visual grading, considering both the
intensity of staining and the proportion of positive tumor
nuclei in the selected sections. Xenograft derived from the
untreated control mice exhibited stronger nuclear staining
than the staining present in nuclei from xenografts in
decitabine treated mice (p < 0.05). These results were con-
sistent with a widespread loss of methylation in U2OS
xenografts derived from the treatment group.
Tumor volumes were determined for all 24 xenografts [see
Additional file 2]. The average volume size for the
xenografted tumors in the control group was 49 mm3 (±
25SD). The xenograft tumors from the decitabine treated
group had an average volume size of 27 mm3 (± 15.9SD)
indicating a significant decrease (p = 0.0096) of tumor
volume as a result of the decitabine treatment (Figure 3A).
All U2OS xenografts were whitish in color and the texture
of tissues from both treatment groups had a moderate-
hard consistency, with no apparent kidney tissue inva-
sion.
Comparison between the U2OS xenograft histology from
the decitabine-treated mice and the control mice identi-
fied differences in bone matrix (osteoid) content. In these
studies relative levels of osteoid were determined in 9 sec-
tions each from the control and decitabine treatment
groups. As shown in Figure 3B, histological analysis of the
stained xenograft sections identified an overall average
osteoid area of 42% in the control group. The decitabine
treated group, however, had a significant increase (p <
0.0001) in osteoid formation reaching up to an average of
86%. With respect to tissue morphology, the tumors from
the control mice showed solid sheets of poorly differenti-
ated cells associated with a small amount of osteoid (Fig-
ure 3C left panel). In contrast, the xenograft tumors from
the decitabine-treated mice showed a less dense cell pop-
ulation with increased areas of osteoid, seen as light pink
and lacy matrix with the nuclei of osteoblasts sitting close
to the matrix, a feature of differentiated osteoblasts in nor-
mal bone (Figure 3C right panel). The mitotic count was
assessed in the same sections (Figure 3D). The mitotic
index showed an average of 11.9 mitotic figures in the
control group and an average of 3.1 mitotic figures in the
decitabine treated group (p < 0.0001).
Since decitabine induced a higher level of cell death in
vitro and there was a marked decrease in the size of U2OS
derived tumors in vivo, the level of apoptotic cells in the
xenograft tumors was analyzed using the TUNEL assay.
Scoring was performed on digital images from 9 control
sections and 9 decitabine treatment sections. The average
Viability and growth kinetics of U2OS in vitro Figure 1
Viability and growth kinetics of U2OS in vitro. A), 
Growth curves of U2OS cells with growth medium alone 
(dark line), or growth medium with one dose of decitabine at 
a final concentration of 1 µM (light graph). The y-axis indi-
cates cell number in millions and the x-axis indicates time 
points in days. The results are expressed as cell counts at 
each corresponding time point. Each data point is the Mean 
of cell counts from 2 experiments (5 passages apart) each 
consist of 2 independent cultures and the error bars indicate 
the standard deviation. The findings indicate a slight increase 
of U2OS cells' doubling time and a decrease of 18% (p = 
0.045) in the viability of treated cells compared to untreated 
control B), Cell death in U2OS cells caused by decitabine 
treatment at 1 µM concentration (light column) compared to 
no-treatment (dark column). The results are expressed as 
percentage of cell death (fraction of cells with positive PI 
stain). The y-axis indicates the percentage of cells with PI 
staining (dead cells). Each column is the Mean of 3 experi-
ments with error bars indicating standard deviation. The 
asterisk indicates significant increase in cell death (p < 0.05) 
as a result of decitabine treatment.Cancer Cell International 2007, 7:14 http://www.cancerci.com/content/7/1/14
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Analysis of differential 5-methylcytidine content of U2OS xenografts using histological sections Figure 2
Analysis of differential 5-methylcytidine content of U2OS xenografts using histological sections. Analysis of the 
relative levels of cellular 5-methylcytidine within xenografts derived from representative control untreated mice (panel A); or 
decitabine treated mice (panel B) using immunohistochemical staining with 5-mc-Ab. To the right a 20X enlargement of repre-
sentative U2OS histology is shown. More 5-mc-Ab staining is evident in the nuclei from control sections (panel A-right side) in 
comparison to nuclear staining in the sections derived from decitabine treated mice (panel B right side). These data are consist-
ent with a reduction in 5-methylcytidine nuclear content in U2OS xenografts derived from mice treated with decitabine. 
Enlargements of darkly stained host murine kidney cells correspond to heavily methylated differentiated renal tissue (denoted 
2 in panels A and B). In panel C the staining intensity from control (dark columns) and decitabine treated (light columns) is 
quantitated using Aperio scanning image analysis of sections. The graph to the right of panel C confirms that the 5-mc-Ab stain-
ing in control untreated (dark columns) U2OS xenograft sections is more intense than the decitabine treated (light columns) 
U2OS xenografts. This decrease in staining intensity was significant (p < 0.05). In contrast host kidney cells from both control 
and treated mice do not exhibit any significant difference in staining intensities.Cancer Cell International 2007, 7:14 http://www.cancerci.com/content/7/1/14
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Induction of differentiation and apoptosis by decitabine treatment of U2OS in vivo Figure 3
Induction of differentiation and apoptosis by decitabine treatment of U2OS in vivo. A), Decitabine effects on 
tumor volumes in vivo. The results compare tumor volumes in control xenografts to decitabine treated xenografts as described 
in methods. Each column is the Mean of tumor volumes measured in 12 xenograft tumors. There was a significant decrease (p 
< 0.05) in tumor volumes as a result of decitabine treatment. B), Osteoid assessment in vivo. Each column is the Mean of oste-
oid evaluation of 9 sections. There was significant increase (p < 0.0001) in osteoid formation as a result of decitabine treat-
ment. C), Representation images of H&E sections. Control xenograft tumors (left) show solid sheets of poorly differentiated 
cells with minimal osteoid (image magnification × 100). Decitabine treated tumors  shows less dense cell population and 
increased areas of osteoid seen as light pink and lacy matrix with the nuclei of osteoblasts sitting closer to the produced matrix 
(image magnification × 100). The arrows in the enlargement  show the osteoid matrix surrounding osteoblasts (defined as eosi-
nophilic osteoid-like material). C), And D), Mitotic count as identified in the same sections used to asses for osteoid evalua-
tion. Each column is the Mean mitotic count in 9 sections (a minimum of 1100 nuclei were scanned per section). Decitabine 
treatment resulted in a significantly lower mitotic count (p < 0.0001). The arrows in the enlargement image in C (left) indicate 
mitotic nuclei. E), Results for apoptosis analysis by TUNEL assay. Each column is the Mean count of TUNEL positive nuclei 
seen in 9 images representing 9 sections (≥1000 nuclei were scanned per section). There was a significant increase (p < 0.05) of 
apoptotic cells as a result of decitabine treatment. F), Representation images from TUNEL assay of control tumors (left) and 
decitabine treated tumors [50] (image magnification × 200). The arrows in the enlargement image show the TUNEL-positive 
nuclei (apoptotic nuclei). Error bars indicate standard deviation from the Mean values and p-values are based on comparison 
between control and decitabine treated tumors using student t-test.Cancer Cell International 2007, 7:14 http://www.cancerci.com/content/7/1/14
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apoptotic indices were 3.2% in the control group and
6.2% in the decitabine treatment group (p = 0.0329) (Fig-
ure 3E and 3F).
Expression profiling of decitabine-induced changes in gene 
expression
Expression profiling of 14,500 transcripts with known
gene function was performed using the Affymetrix U133A
microarrays following treatment of U2OS cells with 1 µM
decitabine. Eighty-eight (88) genes [see Additional file 3]
exhibited significant (p < 0.0025) up-regulation after two
independent treatments of U2OS with 1 µM decitabine.
Within this large group of 88 genes there were 13 with a
≥2-fold change in both experiments (Table 1). The expres-
sion of subset of 7 of these robustly reactivated genes was
examined by real-time PCR and increased gene expression
was consistent with the levels detected by microarray anal-
ysis (Table 1).
An in silico analysis of CpG islands associated with the 88
up-regulated genes was then performed. 63 genes (71%)
were found to contain CpG-islands within their 5'-regula-
tory region. Of the 13 genes with a ≥2fold-change, 11
genes (84%) had a CpG-island within their 5' region
(Table 1). Pathway enrichment analysis was performed on
the 88 up-regulated genes, and the three top enriched
pathways included: "negative regulation of cellular proc-
esses" (p = 0.007), "positive regulation of programmed
cell death" (p = 0.01) and, "organelle organization and
biogenesis" (p = 0.03). Interestingly, when the 13 genes
with a ≥2-fold change were analyzed in the same manner,
six genes were assigned to the "apoptosis pathway" with
high significance (p < 0.0001). These genes include
GADD45A,  HSPA9B,  PAWR,  PDCD5,  NFKBIA, and
TNFAIP3, which were selected for expression validation in
the xenografts and in normal human osteoblasts
(NHOst).
Real-Time expression analysis for apoptotic genes in 
U2OS xenografts and normal osteoblasts
Real-time PCR (TaqMan method) was used to validate
expression of the apoptotic genes shown in Table 1 in the
xenografts and NHOst. As illustrated in Figure 4, the
change of expression was expressed as fold change relative
to the control (no treatment), using beta-actin (ACTB) as
a reference. Up-regulation, as a result of decitabine treat-
ment was consistent in U2OS cells in vitro and in vivo.
Gene expression of the apoptotic genes was up-regulated
up to 8-fold for GADD45A, 8-fold for HSPA9B, 12-fold for
PAWR, 8-fold for PDCD5, 9-fold for NFKBIA, and 5-fold
for TNFAIP3. In addition, real-time expression for the six
genes was examined in normal osteoblasts before and
after treatment with decitabine. There was marginal
increase of expression after treatment (<2-fold change) in
normal osteoblast (Figure 4).
Table 1: Genes up-regulated (p < 0.0025 and ≥2 fold-change) after decitabine treatment identified using AffyChip.
Gene Symbol Fold Change 
(Affy)
Fold Change 
(Real-Time)
CpG known or proposed function
FAM65A 2.76 nd yes hypothetical protein LOC79567
GADD45A 2.58 6 yes Regulation of cyclin dependent protein kinase activity and 
DNA repair
GAGE4 3.51 nd yes Unknown
HSPA9B 2.32 5.3 yes Implicated in the control of cell proliferation and cellular 
aging
IGFBP6 2.22 3 yes Insulin-like growth factor binding protein involved in negative 
regulation of cell proliferation
IMP-3 8.36 nd yes Binds to insulin-like growth factor II leader 3 mRNA and may repress 
its translation during late development
NFKBIA 4.01 4.2 yes Inhibits NF-k-B and involved in cell adhesion, apoptosis, 
differentiation and growth
PAWR 3.30 10 yes Pro-apoptotic protein acts by down-regulating the anti-
apoptotic protein BCL2 via its interaction with WT1
PDCD5 4.15 8 yes Induction of programmed cell death
PSG5 2.32 nd no Synthesized by syncitiotrophoblast of the placenta and has a role in 
maintenance of gestation
RAC2 5.09 nd no Involved in the regulation of the NADPH oxidase
TGM2 2.01 nd yes A peptide cross-linking factor
TNFAIP3 3.44 4.5 yes Negative regulation of I-k-B kinase/NF-k-B cascade
Fold change (Affy) is the Mean from a duplicate AffyChip experiments. The fold change using real-time PCR (TaqMan method) is the Mean values 
from the same RNA from the same yields that were used for the AffyChip experiments and a third replica. The direction of expression was 
consistent in the Affy experiment and the real-time experiment for the tested genes. 11 out of 13 genes have CpG-island in there 5' region. Genes 
in bold characters are those identified in the apoptotic pathway as explained in "Methods" and "Results". The genes are listed in alphabetical order.Cancer Cell International 2007, 7:14 http://www.cancerci.com/content/7/1/14
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DNA methylation analysis of decitabine responsive genes 
using Pyro Q-CpG
Methylation Pyro Q-CpG sequencing analysis was per-
formed on six genes with expression up-regulation after
decitabine treatment including GADD45A,  HSPA9B,
PAWR,  PDCD5,  NFKBIA, and TNFAIP3.  GADD45A,
HSPA9B,  PAWR, and PDCD5, but not NFKBIA, and
TNFAIP3, showed reliable and reproducible results for the
tested amplicons. GADD45A, PAWR, and PDCD5 had a
high methylation content (>70%) without decitabine
treatment, while HSPA9B had an intermediate (50% –
70%) methylation content. Decitabine treatment lowered
the methylation content in all CpG sites tested for the four
genes in vitro and in vivo (Figure 5). Induction of demeth-
ylation was most marked for PAWR, and PDCD5.
GADD45A  had intermediate loss of methylation and
HSPA9B had the least change but overall methylation loss
remained significant. Analysis of relative change in meth-
ylation was also performed on normal osteoblasts, which
had an initial low methylation content comparable to the
negative control (DNA from early embryos), and no
change in this basal content was apparent following decit-
abine treatment.
More detailed results on the methylation status for the
same four genes for all tested CpG positions is provided in
Figure 6 [also see Additional file 4]. For GADD45A, a CpG
rich sequence at the promoter region containing a cluster
of eight CpG positions was tested by Pyro Q-CpG. In
U2OS cells, the methylation percentage on the eight CpG
positions had an average of 83% in the no-treatment
(control) cells. This was reduced to an average of 44%
after treatment with 1 µM decitabine (p < 0.001). Simi-
larly, the no-treatment xenograft tumors had averages of
84% in Xeno-1, 81% in Xeno-2, and 85% in Xeno-3,
which was reduced after three doses of 2.5 mg/kg decitab-
ine to 46%, 43% and 37% in Xeno-4, Xeno-5 and Xeno-6
respectively (p < 0.001).
A CpG rich sequence at the promoter region of HSPA9B
had a cluster of 13 CpG positions which were tested by
Pyro Q-CpG. The overall methylation quantity seen in
this sequence was lower than what was observed in
GADD45A, none-the-less the difference between the no-
treatment (control) samples and decitabine-treated sam-
ples was significant (p < 0.001). U2OS cells (in vitro) had
an average of 59% before treatment, and 42% after treat-
ment (p < 0.001). Before treatment, the xenograft tumors
had averages of 61% in Xeno-1, Xeno-2, and Xeno-3
which was reduced after treatment to an average of 49%
in Xeno-4 and Xeno-5 and 43% in Xeno-6 (p < 0.001).
The analysis was done in the same manner for 13 and 12
CpG positions related to the CpG-island associated with
PAWR and PDCD5 respectively. These two genes had very
high methylation percentage before decitabine treatment
in U2OS, Xeno-1, 2, and 3 for the tested CpG positions. In
the case of the 13 CpG positions tested in PAWR the aver-
age of methylation percentage before decitabine treat-
ment was 93% in U2OS cells, 93% in Xeno-1 and Xeno-2,
and 94% in Xeno-3. After decitabine treatment, this was
reduced significantly (p < 0.001) to an average of 26% in
U2OS cells, 29% in Xeno-4 and 28% in Xeno-5 and 6. In
the 12 CpG positions tested in PDCD5, U2OS cells had an
average of 93%, Xeno-1 had an average of 94, Xeno-2 had
an average of 93%, and Xeno-3 had an average of 92%
before decitabine treatment. The methylation was
reduced significantly after decitabine treatment (p <
0.001) to 26% in U2OS cells, Xeno-4, and Xeno-5, and
27% in Xeno-6.
The normal low-passage osteoblast had a very low meth-
ylation percentage in all 4 genes. The range of methylation
percentage had averages from 2.1% to 3.6% before treat-
ment, and 1.4% to 2.7% after treatment with 1 µM decit-
Real-time gene expression of 6 pro-apoptotic genes U2OS in  vitro &in vivo and normal osteoblasts Figure 4
Real-time gene expression of 6 pro-apoptotic genes 
U2OS in vitro &in vivo and normal osteoblasts. Total 
RNA was extracted from U2OS cells in vitro and in vivo and 
reverse-transcribed as detailed in methods. TaqMan assays 
were used to determine relative expression using the cDNA 
from control (no treatment) as base lines and ACTB for a ref-
erence gene by applying the ∆∆Ct method. Each column is 
the Mean of three replicas and error bars indicate standard 
deviation from the Mean. The data is expressed as fold 
change relative to control (no-treatment). Xeno-4, Xeno-5, 
and Xeno-6 = decitabine treated xenografts. NHOst = nor-
mal human osteoblasts.Cancer Cell International 2007, 7:14 http://www.cancerci.com/content/7/1/14
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abine across all the tested CpG positions in the 4 genes
(Figure 5, Figure 6 and [Additional file 4]). Importantly,
the methylation status of the tested CpG sequences
reflects the patterns of expression seen in all four genes
after decitabine treatment in U2OS cells and xenografts.
This is consistent with the possibility that decitabine treat-
ment modulated the expression through reducing the
amount of methylation on CpG-dinucleotides. To deter-
mine whether decitabine activated GADD45A  methyla-
tion status and expression was also tested in two other OS
cell lines, MG63 and HOS using identical decitabine treat-
ment conditions. Similar to U2OS, induction of
GADD45A gene expression was associated with significant
loss of methylation and increased transcript expression in
MG63 cells. However in HOS cells, treatment had no sig-
nificant demethylation effect on the GADD45A promoter
regions and also failed to activate expression of the gene
(data not shown).
Discussion
This study draws attention to the possibility that thera-
peutic levels of decitabine could orchestrate the interplay
between DNA damage genes, induce growth arrest, apop-
tosis and potentially modulate genomic fidelity. At
present, neoadjuvant and adjuvant chemotherapy is
favored in the treatment of OS and the agents most com-
monly used include doxorubicin, high-dose methotrex-
ate, cis-platinum and ifosfamide either alone or with
etoposide. The use of these agents in OS treatment has
been well established and yielded 5-year disease-free-sur-
vival and overall-survival of greater than 60%, (reviewed
in [21]). However, the lack of a near-complete response to
chemotherapy in a sub-group of patients reflects inherent
biologic resistance to these agents, hence poorer progno-
sis [22], especially since attempts at changing chemother-
apy regimens for poor responders have generally not
improved outcome [23-25]. In recent years, another
Comparison of percentage of methylation across 5 of the tested CpG positions in vitro and in vivo Figure 5
Comparison of percentage of methylation across 5 of the tested CpG positions in vitro and in vivo. Each data 
point is the average of methylation percentage for each CpG position in three experiments. Y-axis indicates the percentage of 
methylation and the samples are indicated on the x-axis. The location of CpG positions relative to the gene start site and to 
each other is shown in Figure 5. The results of 5 CpG positions are shown to represent the methylation percentage in the four 
genes across the samples. There was a significant decrease (p < 0.001) in methylation quantity for each CpG position after 
decitabine treatment both in vitro and in vivo for the four genes in all sample but not in the NHOst (normal human osteoblasts). 
p-values were calculated by comparing the percentage of methylation for each individual CpG position in control cells with the 
same CpG position in the treated cells using student t-test and they all resulted in p < 0.001.Cancer Cell International 2007, 7:14 http://www.cancerci.com/content/7/1/14
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approach that has been used in other tumors is targeting
the epigenome of tumor cells. The most promising of
which is the re-activation of epigenetically silenced genes,
using DNA methylation inhibitors or histone deacetylase
inhibitors (HDAC) [26-28].
Previous studies have implicated a role of epigenetics in
OS biology; Methylation of osteocalcin has been linked to
bone differentiation [9-11], transcription factor expres-
sion, and histone modifications [12,13]. Abnormal pro-
moter methylation of p16INK4a/p14ARF promoters was
observed in OS-derived cell lines [29]. Aberrant methyla-
tion of specific genes was also correlated with poor sur-
vival in OS patients [30,31]. The number of genes found
methylated in OS is increasing [32,33] which further sup-
ports the implication of DNA methylation in OS tumori-
genesis.
Up-to-date studies regarding the epigenetics OS have
either been based on a single gene or focused on a small
number of genes, and limited with respect to elucidating
the target pathways suitable for epigenetic therapeutics in
OS. Our study is the first to use demethylation treatment
to modify global gene expression in an OS cell line in
order to identify pathway-specific methylation targets that
may have therapeutic importance. Analysis of decitabine-
induced cellular changes in U2OS xenografts suggested
that apoptotic pathways may be the earliest pathways to
be affected. The decitabine dose was based on previous
studies [34-36] and has been shown to reduce the methyl-
ation of tumor suppressor genes and decrease tumor
growth in xenografts. The xenografts in decitabine-treated
mice decreased in volume size significantly (p < 0.05)
when compared to the xenografts in untreated control
mice. Recent reports showed similar effects of xenograft
size and growth parameters from other tumor types grown
in mice treated with decitabine [37,38].
The effect of decitabine on tumor cell mitotic index, apop-
tosis and extracellular matrix (osteoid) formation in OS
has not been previously reported. In our series, decitabine
treatment significantly decreased the number of mitoses
and increased the number of apoptotic cells. In addition,
treatment with decitabine significantly increased the
amount of osteoid associated with the tumors. Such
results suggest that decitabine treatment reduces the pro-
liferative capacity of U2OS cells, whilst concurrently driv-
ing the cells toward terminal differentiation and
apoptosis.
Gene expression profiling by microarray analysis showed
that 88 genes showed increased expression in vitro after
decitabine treatment, which represented 0.6% out of the
14500 genes on the array and this global modulation of
genes is at a level comparable to other studies. The effect
Summary of Pyro-Q-CpG findings Figure 6
Summary of Pyro-Q-CpG findings. Illustrated are the 
summary findings by Pyro-Q-CpG analysis of U2OS cells in 
vitro without treatment (control) and with 1 µM decitabine 
treatment (treated). The illustration also summarizes Pyro-
Q-CpG findings in control U2OS xenograft tumors (Xeno-1, 
Xeno-2, and Xeno-3), and 2.5 mg/kg decitabine treated 
U2OS xenograft tumors (Xeno-4, Xeno-5, and Xeno-6). 
DNA from NHOst (normal low-passage human osteoblasts) 
was also analyzed for experiment control. DNAs from early 
embryonic DNA (Emb-DNA) and universally methylated 
DNA (Met-DNA) were used for negative and positive con-
trol respectively. CpG-islands are denoted by grey rectangles 
relative to the gene start site. The region further enlarged 
below corresponds to each tested CpG sequence. The tick 
marks denotes the individual CpG dinucleotides. The tran-
scription start site is indicated by a directional arrow with 
the base pair numbers annotated for each tested sequence. 
The extent of methylation is represented by the scale bar 
(bottom right). GADD45A, PAWR, and PDCD5, had a high level 
of methylation before decitabine treatment while HSPA9B 
had an intermediate level of methylation before treatment. In 
all cases the methylation was decreased significantly (p < 
0.001) as a result of decitabine treatment. The detailed 
results for all genes are shown in [Additional file 4].Cancer Cell International 2007, 7:14 http://www.cancerci.com/content/7/1/14
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of decitabine on global gene expression has been previ-
ously reported in several studies [39-41]; comparable to
our study, the number of up-regulated genes varied from
1.9% in ovarian cancer cells [40] to 1.1% in malignant gli-
oma cells [41] and 0.6% in bladder cancer cells [39]. The
differences in the number of decitabine up-regulated
genes were possibly a result of cell line-to-cell line varia-
tions, microarray platforms, and experimental designs
including differences in drug dosage and duration of treat-
ment. Indeed, Karpf et al [42] screened the expression of
approximately 38,000 human transcripts in several decit-
abine treated cell types and observed changes in genes
expression for 0.2 to 1.4% of those transcripts, depending
on the cell type treated [42] and (reviewed in, [43]). Fur-
ther investigation of several OS cell lines will further assist
to more accurately define the level of global change of
expression induced by decitabine using the same experi-
ment conditions and microarray platform.
The global expression profiling of U2OS represents the
majority of cells that were viable at the time of harvest.
These cells were undergoing fine molecular modulations
of their epigenome eventually leading to changes in gene
expression resulting in the observed cell death and apop-
tosis in vitro and in vivo. Decitabine treatment in U2OS
induced a level of cell death that was comparable to obser-
vations in acute myeloid leukemia (AML) cells using sim-
ilar treatment regimens in vitro [44]. In this study
differentiation activation was considered to be an early
effect of decitabine in AML. The genes identified in U2OS
with a role in apoptosis were GADD45A, HSPA9B, PAWR,
PDCD5,  NFKBIA, and TNFAIP3. These proteins have
potential roles in regulating a number of key apoptotic
events including the p53 related apoptosis, bcl2 related
apoptosis, and the nfkb related apoptosis [40-50]. While
the exact function of GADD45A is not known, the protein,
like p53, is considered to be involved in cell growth con-
trol, maintenance of genomic stability, DNA repair, cell
cycle control, and apoptosis. Interestingly, Gadd45a has
recently been shown to promote epigenetic gene activa-
tion by repair-mediated DNA demethylation [45].
The findings of this study suggest that the cellular effects
detected are a result of up-regulation of apoptotic genes.
These data are in general agreement with the increasing
evidence that decitabine's antineoplastic effects may be
through modulation of apoptotic pathways [46,47]. Our
data also demonstrate that the re-activation of genes
involves CpG-island demethylation. Dinucleotide clusters
of CpGs in CG-rich regions of genomes or CpG-islands
are present in the promoters and exonic regions of at least
40% of mammalian genes some reports, however, other
reports indicate that up to 70% of mammalian genes have
CpG islands in their promoter [48,49]. Methylation of
promoter associated CpG islands in the genome of cancer
cells has shown non-random and tumor-type-specific pat-
terns [50]. While some tumors exhibit hypermethylation
of low number of specific CpG islands, other tumors pos-
sess hypermethylation of a higher number CpG island
associated promoters [50]. It is important, though, to real-
ize that not all genes with methylated CpG islands are re-
activated by decitabine treatment possibly because some
methylated CpG islands may have other chromatin struc-
tural alterations that are dominate over DNA methylation
for their silencing, (reviewed in [43]).
In our study, 63 (71%) of the 88 decitabine up-regulated
genes possessed CpG-island at their 5' region, a propor-
tion that is higher than that observed in other reports;
including AML [44], and human glioma cell lines, where
decitabine re-activated 50% and 40%, respectively, of
genes with potential CpG islands [50]. This observation is
particularly intriguing because it suggests that decitabine
treatment of U2OS induced CpG-island associated genes
more frequently than previously reported. Moreover, of
the 13 U2OS genes with a ≥2-fold change, there were 11
genes (84%) with CpG-island in there promoter region.
The further enrichment of the frequency of CpG-island-
associated genes in the genes with a strong induction of
expression (≥2-fold change) after decitabine treatment,
further suggested that expression induction reflects either
a more direct effect of decitabine through CpG-island
demethylation, or indirect activation effects. In four of six
apoptotic genes studied in detail, we showed a significant
increase in expression following decitabine treatment was
accompanied by a marked loss of promoter methylation,
which points out to the potential direct effect of decitab-
ine on methylated CpG sequences. Decitabine-induction
of GADD45A expression was examined in two other oste-
osarcoma cell lines (MG63 and HOS), to determine the
specificity of this effect. Whilst MG63 responded in a sim-
ilar way to U2OS, HOS did not become demethylated in
the promoter region of GADD45A, and expression was
not activated by decitabine. These data are consistent with
cell-type differences in response to this drug (Al-Romaih
et al., in preparation), and the notion that mechanisms
other than demethylation may effect a subset of genes in
some cell types. Interestingly, out of 88 significantly
induced genes there were 25 genes with no apparent CpG
island at their promoter region. Similarly, two genes out
of the 13 genes with ≥2-fold change have no potential
CpG islands close to the TSS and promoter region. Meth-
ylation-independent induction of gene expression has
also observed in other studies [39,51,44] indicating that
genes without CpG islands may respond to this drug.
Decitabine mechanism of action is not restricted to its
demethylation capability and was reported to have effects
on histone methylation and RB phosphorylation [52,53].
This also draws attention to the possibility that the other
two apoptotic genes (NFKBIA, and TNFAIP3) wereCancer Cell International 2007, 7:14 http://www.cancerci.com/content/7/1/14
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expressed by induction of methylation-independent
mechanisms.
Decitabine treatment re-activated several apoptotic genes
in U2OS cells that were identified in this work. Our
microarray screen also identified other decitabine re-acti-
vated genes with potential roles in regulating proliferation
and differentiation of mammalian cells. IGF-binding pro-
teins IGFBP6 and IMP-3 (Table 1) have been shown to be
potential regulators of IGFs with anti-growth properties
[54-57]. Hypermethylation of these genes functions as a
mechanism for increased proliferation capacity, reduction
of apoptosis and loss of the differentiated phenotype in
U2OS. Targeting hypermethylation in U2OS by decitab-
ine indicated the potential power of this drug for OS treat-
ment.
Conclusion
Our data suggest that a number of pro-apoptotic genes
were silenced by methylation in U2OS. Hypermethyla-
tion of GAD45A, HSPA9B, PAWR, PDCD5 in U2OS sug-
gest that apoptosis is a target pathway for OS epigenetic
drug intervention. These genes would be ideal markers for
successful induction of demethylation in OS-derived cells,
OS primary cells, and OS clinical trials.
Methods
Cell line culture and treatment
The human OS cell line U2OS was obtained from the
American Type Culture Collection (ATCC) (Rockville,
MD) and maintained in alpha-Minimum Essential
Medium (alpha-MEM) supplemented with 10% heat
inactivated Fetal Bovine Serum and 2 mM L-Glutamine.
Treatment with decitabine was performed as described by
Liang et al [39]. Briefly, 5 × 105 cells were plated in 56 cm2
culture plates with 10 ml growth medium. 12 hours after
plating they were treated with freshly prepared decitabine
(Sigma Chemical Co., St Louis, MO) to a final concentra-
tion of 1 µM without changing the medium. The cells
were harvested by trypsinization after 3 days of treatment,
where the cells were portioned and used for total RNA
extraction, DNA extraction, or Propidium Iodide (PI)
staining for cell death by flow cytometery. A control
(medium only) culture was maintained and processed
over the same period of time under the same condition as
the treated cells. To establish growth curves for U2OS cells
with or without 1 µM decitabine, cells were plated at 5 ×
105 cells/56 cm2 culture plates with 4 mm2 grids. The cells
were allowed to attach to the surface of the plates for 12
hours before the start of the treatment. Adherent cells
were counted in 2 independent cultures in multiple 4
mm2 grids every 12 hours after plating and the experiment
was repeated after culturing the cells for 5 passages. When
cell growth was near confluent, the cells were trypsinized,
re-suspended in growth medium (10% serum) and cell
viability was determined using Vi-CELL™ XR (Beckman
Coulter, Fullerton, CA) after Trypan Blue staining.
Immunohistochemistry and image analysis
Xenograft tissue sections were de-paraffinized using
xylene and re-hydrated in a series of alcohols. The tissue
sections were then incubated at room temperature (RT) in
3% H202 in PBS for 10 minutes to inactivate endogenous
peroxidase. Following incubation the slides were washed
3 times in PBS for 3 minutes each. Antigen retrieval was
obtained by heating in a microwave at maximum heat for
20 minutes in Tris-EDTA buffer (10 mM Tris Base, 1 mM
EDTA solution, 0.05% Tween 20, pH 9.0) and cooling for
20 minutes at RT. Slides were again washed 3 times in PBS
for 3 minutes each. The slides were blocked (30 minutes
in a humid chamber at RT) with serum to reduce non-spe-
cific binding. Serum was removed from the slides and the
slides were then incubated with the primary antibody 5-
methylcytidine (5-mc-Ab) (Eurogentec, San Diego, CA) at
1:500 dilution at 4°C overnight.
Following incubation the slides were washed 3 times in
PBS for 3 minutes each. The slides were then incubated
with a secondary antibody [Polyclonal rabbit anti-mouse
immunoglobulins/biotinylated rabbit F(ab')2; Dako] for
30 minutes at RT, followed by 3 washes in PBS for 3 min-
utes each. The slides were then incubated with StreptABC-
Complex/HRP (Dako, Glostrup, Denmark) for 30
minutes in a humid chamber at RT, followed by 3 washes
in PBS for 3 minutes each. A 3,3'diaminobenzidine (DAB)
substrate (Vector Laboratories, Burlingame, CA) was used
for detection and hematoxylin was used for counterstain.
The slides were then dehydrated and mounted.
Whole sections from xenografts were scanned by
ScanScope CS (Aperio technologies, Vista, CA). The slides
were digitized to 20× magnification (~0.5 microns/pixel).
Images were then viewed with Aperio's image viewer soft-
ware (ImageScope), which allows performing quantita-
tive analysis of stain intensity on snapshots from the
sections. Five to ten ~0.3 mm2 snapshots (each containing
3,000 to 5,000 cells) were analyzed per section using the
following parameters: compression quality = 30, and
color saturation threshold = 0.04. Positivity thresholds
were150 to 220 = high positive, 100 to 150 = low positive,
and 0 to 100 = negative. Descriptive analysis such as mean
and standard deviation for 5-mc immunostaining inten-
sity were calculated based on the percentage of positivity
(total positivity/total negativity per snapshot). Compari-
son between control and decitabine-treated sections was
done using the student t-test and p < 0.05 was considered
significant.Cancer Cell International 2007, 7:14 http://www.cancerci.com/content/7/1/14
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In vivo studies: U2OS xenograft and treatment
Six- to eight-week old male immune-deficient NOD-SCID
and Rag-2M mice were bred and maintained by the Ani-
mal Resource Centre at the British Colombia Cancer
agency, Vancouver, Canada. U2OS cells, in general, were
considered as non-tumorigenic in mice while grafting the
cells subcutaneously or orthotopically [17]. As such, in
order to establish their xenografts, U2OS cells were
grafted under the renal capsule, a site proven to be an
excellent site for tumor engraftment [18-20]. Briefly U2OS
cells were cultured in alpha-MEM and washed in growth
medium containing 20% FBS. The viable cells were
counted after trypan blue staining. 2 × 106 cells were pel-
leted, re-suspended and grafted beneath the renal capsule
of adult male SCID mice as previously described [18].
After 5 months, a well-grown xenograft was selected for re-
grafting to establish multiple stable U2OS xenografts
under the kidney capsules of NOD-SCID mice (two per
kidney per mouse). The re-grafted U2OS xenograft had a
100% take rate, with a doubling time of ~10 days and
exponential growth phase starting after ~2 of tumor
growth doubling. After 5 generations of tumor growth
doubling the xenografts were surgically removed from the
mice and cut into approximately 4 mm3 portions then
were re-grafted under the renal capsules of 6 male Rag-2M
mice (4 grafts per mouse, 2 per kidney). Four weeks after
grafting (~2–3 doubling of tumor growth), the host mice
were divided into two groups. One group (3 mice) was
given decitabine (2.5 mg/kg body weight) dissolved in
saline (0.9% w/v NaCl), intraperitoneally [8] on days 29,
31 and 33. The other group (3 mice) was given saline
alone as a treatment control over the same schedule. On
day 37, mice from both groups were sacrificed. Tumor vol-
umes were measured using a digital caliper, recorded and
expressed in mm3, using the formula: volume (mm3) =
(0.52) × length (mm) × width (mm) × height (mm). Data
were presented as means ± Standard Deviation (SD) and
student t-test was used to analyze the difference between
the two treatment groups. The xenograft tissues were then
snap frozen, or prepared in paraffin and sectioned accord-
ing to standard procedures [18].
Histopathological analysis and TUNEL assay
The tissues from the control (no treatment) and decitab-
ine treated groups were paraffin embedded using routine
protocols [18] and stained with hematoxylin and eosin.
Sections were assessed blindly. Extracellular matrix was
defined as eosinophilic osteoid-like material surrounding
individual cells and small clusters of 3–5 cells, and the
percentage of tumor with osteoid was then calculated.
Mitotic counts were performed in areas with the highest
mitotic rate, and ten high-powered fields (× 400) were
counted per section.
In situ hybridization for terminal deoxynucleotidyl trans-
ferase-mediated nick end labeling (TUNEL) was per-
formed on paraffin sections as recommended by the
manufacturer (Ventana Medical Systems, Tucson, AZ).
Scoring of the sections was performed using Simple PCI
analytical software (Nikon, Tokyo, Japan). Sections were
examined and the most intense areas of staining were
photographed using a DXM1200 digital camera (Nikon)
at a power of x200. The digital image was then scanned
using the Simple PCI program and the numbers of posi-
tive and negative nuclei were obtained. Control and treat-
ment images were all photographed at a uniform
brightness, and all images were subjected to uniform
binary image modification and size calibration prior to
counting by Simple PCI. The positivity index was
obtained by dividing the number of positive nuclei by the
total number of nuclei (positive + negative). The number
of nuclei counted was always over 1000, and ranged from
1100 to 2000. Positivity indices were compared by Stu-
dent's t-test and a p-value of <0.05 was considered signif-
icant.
Affymetrix expression analysis
Total RNA was extracted using the RNeasy kit (Qiagen,
Germany) from duplicate experiments of U2OS cells at
day 3 after treatment with 1 µM decitabine or medium
alone (control). In each experiment RNA yields were
pooled from two independent cultures per treatment arm
to minimize experimental noise. For each case, 10 µg of
RNA was labeled and hybridized to the Affymetrix HG-
U133A GeneChips using the manufacturer's protocol
(Affymetrix, Santa Clara, CA) by the Centre of Applied
Genomics at the Hospital for Sick Children (Toronto,
Canada). Data were extracted using the Microarray Suite
(MAS) version 5.0 (Affymetrix) and linearly scaled to
achieve an average intensity of 150 across each chip. The
candidate gene list obtained from the MAS 5.0-extracted
data was selected by eliminating genes that were not
present in at least one experiment. The arrays were sub-
jected to a pair wise comparison using MAS 5.0, with sig-
nal intensities from the no-treatment cells as the baseline.
The statistical significance for the change of expression for
each probe set between the decitabine treated and control
was calculated by the MAS 5.0 software. The criteria for
gene selection for real-time expression validation analysis
was based on the statistically significant up-regulation (p
< 0.0025) and fold change of ≥2 for expression after decit-
abine treatment. The gene list was annotated based on the
NetAffx data-base [58] and further verified using the
Human Genome Browser data base [59]. All the raw data
for expression arrays is available in [60] under the series
record number (GSE7454).Cancer Cell International 2007, 7:14 http://www.cancerci.com/content/7/1/14
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In silico analysis of CpG-island association, gene 
annotation, and pathway enrichment
The criteria for a CpG-island was based on those outlined
by Takai and Jones [61], where the GC ≥ 55%, Obs/Exp ≥
0.65, and length > 300 bp which was reported to exclude
most Alu-repetitive elements. We identified the genes that
harbored CpG-island within a 2000 bp window upstream
or downstream from the transcription start site based
Human Genome Browser data base [59]. To be certain
that there were no CpG island closer to the TSS and gene
promoter regions, we submitted the sequences of interest
(including a 2000 bp window upstream and downstream
from TSS) to the CpG search engine available in reference
[61] and verified that there was no CpG islands that are
closer to TSS for the genes we tested. Up-regulated genes
with CpG-island associations were further analyzed
through the Microarray Literature-based Annotation tool
MILANO [62] to look for evidence of epigenetic modifica-
tions in the literature. MILANO is a web-based tool that
allows annotation of lists of genes derived from microar-
ray results by user defined terms [62]. Using MILANO we
searched for literature associations between our list of
genes and the terms 'epigenetics', 'methylation' 'chroma-
tin modification' 'cancer', and 'disease'. To identify the
putative functional pathways for each gene list, we used
the functional annotation enrichment tool. This tool uti-
lizes the Gene Ontology database and uses GO Terms to
identify enriched biological themes in the gene lists
[63,63]. The Fisher Exact test was applied to determine the
significance in the proportions of genes falling into a cer-
tain pathway in each gene list. We used this tool to look
for enriched pathways of up- or down- regulated genes
with CpG-island associations from the gene lists from the
cell lines.
Expression validation using reverse transcription and 
quantitative real-time PCR
Total RNA from xenografts was extracted using the TRIzol
reagent method. 1 ml of TRIzol (Invitrogen, Osaka,
Japan) was used for every 50–100 mg of tumor tissue and
homogenized in an RNase free environment. Chloroform
was then added (200 µl for each 1 ml TRIzol) and the
samples were centrifuged at high speed for 15 minutes at
4°C. The aqueous layer was then transferred into a new
tube and RNA was precipitated with iso-propanol fol-
lowed by one wash using 70% ethanol. The RNA precipi-
tate was then dissolved in 10–15 µl of RNAse free water
and analyzed for quantity and quality using a spectropho-
tometer. A two-step reverse transcription-PCR procedure
was performed. Total RNA was reverse transcribed using
the GeneAmp kit (Applied Biosystems; ABI, Foster City,
CA). 20 ng of the resulting cDNA was then used in the
real-time PCR step. Six genes were tested by real-time PCR
including: growth arrest and DNA-Damage inducible, alpha
(GADD45A), heat chock70KDA protein 9b (HSPA9B), parkc
apoptosis wt1-regulatort (PAWR), programmed cell death 5
gene (PDCD5), nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, alpha (NFKBIA), tumor necrosis
factor, alpha-induced protein 3 (TNFAIP3) .  W e  u s e d  t h e
TaqMan primers (ABI) for all the genes that we tested
(primer information is provided the in [Additional file
5]). All real-time PCR assays were performed in triplicate
in a 96-well plate using the 7900 Sequence Detector Sys-
tem (ABI) according to the manufacturer's protocol. Data
analysis was performed using the Sequence Detector Sys-
tem (SDS) software (ABI) and the results were expressed
as fold-change in relative mRNA expression level, calcu-
lated using the ∆∆Ct method with β-actin (ACTB) as the
reference gene and the non-treated cells as baseline. The
validation was carried out on RNA from three replicate
experiments of U2OS cells, three decitabine-treated U2OS
xenograft tumors (Xeno- 1, 2 and 3), three no-treatment
(control) U2OS xenograft tumors (Xeno- 4, 5, and 6) and
three replicate experiments of NHOst.
Quantitative-bisulfite pyrosequencing
Quantitative Bisulfite Pyrosequencing for CpG islands
(Pyro Q-CpG) is a sequencing-based analysis of DNA
methylation that quantifies multiple CpG sites per ampli-
con using Pyro Q-CpG software. 2 µg of DNA from the
control and decitabine treatment were bisulfite-treated
using the Zymo DNA Methylation Kit (Zymo Research,
Orange, CA). Bisulfite-treated DNA was amplified by PCR
then sequenced according to the manufacturer's protocol
(Biotage, Kungsgatan, Sweden). The target sequences
inside the CpG-islands of the candidate genes and the
primer sequences are shown in [Additional file 5]. The
percentage of C content (methylated alleles) versus T con-
tent (unmethylated alleles) is calculated by the Pyro-Q-
CpG software for each CpG position in each sample. Anal-
ysis was performed on DNA samples from 3 replicate
experiments of U2OS cells in vitro and six U2OS xenograft
tumors; three decitabine treated (Xeno-1, Xeno-2 and
Xeno-3), and three saline (control) treated (Xeno-4, Xeno-
5 and Xeno-6). Universally methylated DNA was used as
a methylation positive control. DNA isolated from early
embryos (Biotage, Kungsgatan, Sweden) was used for
methylation negative control. DNA from low-passage
normal human osteoblasts (PromoCell, Germany) was
used for experiment control.
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